Pancreatic Cancer Research

ResearcherUniversity of Nebraska Medical CenterActive in the last 2 years

Jane L. Meza

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112478237, A5112903906; NIH RePORTER profile ID 8578386. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
25
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 grant

Papers 8

  1. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Co-author DOI 10.1016/j.ctro.2020.06.003↗
  2. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. Co-author DOI 10.1186/s12885-020-07016-8↗
  3. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective anal… Co-author DOI 10.1186/s13014-020-01569-5↗
  4. The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National… Co-author DOI 10.3389/fonc.2020.01518↗
  5. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.radonc.2018.11.002↗
  6. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic A… Co-author DOI 10.1097/coc.0000000000000599↗
  7. Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation. First author DOI 10.1038/bjc.2016.116↗
  8. Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis. Co-author DOI 10.18632/oncotarget.2990↗

Grants 1

  1. Targets, Modulators and Delivery Program P30CA036727↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer D. Black · 1 shared grant, 2026 · strength 0.86
  2. Kenneth H. Cowan · 1 shared grant, 2026 · strength 0.86
  3. Sarah A Holstein · 1 shared grant, 2026 · strength 0.86
  4. Chi H. Lin · 6 shared papers, 2019–2020 · strength 0.79
  5. Saber Amin · 4 shared papers, 2020 · strength 0.62
  6. Michael J. Baine · 4 shared papers, 2020 · strength 0.62
  7. Chandrakanth Are · 2 shared papers, 2019 · strength 0.17
  8. Jean L. Grem · 2 shared papers, 2019 · strength 0.17
  9. Vivek Verma · 2 shared papers, 2019 · strength 0.17
  10. Michael Anthony Hollingsworth · 2 shared papers, 2015–2019 · strength 0.12
  11. Surinder K. Batra · 2 shared papers, 2015–2016 · strength 0.11
  12. Shuo Wang · 1 shared paper, 2019 · strength 0.09
  13. Lyudmyla Derby Berim · 1 shared paper, 2019 · strength 0.08
  14. Seema Chugh · 1 shared paper, 2016 · strength 0.08
  15. Moorthy Palanimuthu Ponnusamy · 1 shared paper, 2016 · strength 0.08
  16. Richard G. MacDonald · 1 shared paper, 2015 · strength 0.04
  17. Poomy Pandey · 1 shared paper, 2015 · strength 0.04
  18. Haley L. Peters · 1 shared paper, 2015 · strength 0.04
  19. Srustidhar Das · 1 shared paper, 2015 · strength 0.04
  20. Parthasarathy Seshacharyulu · 1 shared paper, 2015 · strength 0.04
  21. Dhanya Haridas · 1 shared paper, 2015 · strength 0.04
  22. Sukhwinder Kaur · 1 shared paper, 2015 · strength 0.04
  23. Prakash Radhakrishnan · 1 shared paper, 2015 · strength 0.04
  24. Joyce C. Solheim · 1 shared paper, 2015 · strength 0.04
  25. Satyanarayana Rachagani · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.